SecBot SecBot
PTAB-TRIAL ·Filed Nov 10, 2026

NVS

NOVARTIS AG
NEUTRAL
Impact 3/10
Horizonmonths Processed6d 10h ago PTABPTAB Decision · ptacts.uspto.gov
PTAB institution decision (instituted)
Actionable Insight • Neutral

Monitor the PTAB trial schedule and any related district court or ITC litigation for materiality. A final written decision finding claims unpatentable could affect Novartis's exclusivity for its anti-IgE food allergy therapy, but the current institution is only a procedural step.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$163.26
T+0 close · Nov 10, 2026 · via day close
Latest settled
−1.80%
T+1 · $160.32
Vs SPY
−3.12%
α at T+1
Next horizon
T+5
in 7h
  1. T+0 · Nov 10 $163.26entry
  2. T+1 · 6d ago −1.80%α −3.12% · $160.32
  3. T+4 · todayOpen
  4. T+5 · in 7h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

Executive Summary

The PTAB granted institution of IPR2026-00260, allowing Amneal and Kashiv to challenge claims of Novartis's patent covering anti-IgE antibody therapy for multiple food allergies. As an interlocutory ruling, no claims have been cancelled, and the patent remains in force pending a final written decision.

PTAB Trial Details

Proceeding
IPR2026-00260
Proceeding Type
IPR (inter partes review)
Decision
Trial instituted
Company Role
Patent owner
Outcome for Patent Owner
Pending (trial to come)
Patent
U.S. 12,030,959
Patent Covers
anti-IgE antibody therapy for multiple food allergies
Challenged Claims
not stated
Next Step
Final written decision expected within approximately one year

Key Facts

  • PTAB granted institution of IPR2026-00260 on November 10, 2026
  • Patent U.S. 12030959 covers anti-IgE antibody therapy for multiple food allergies
  • Patent owner is Genentech Inc. and Novartis Pharmaceuticals Corp. (Novartis AG subsidiary)
  • Petitioners are Amneal Pharmaceuticals, Inc. and Kashiv Biosciences, LLC
  • Institution is interlocutory; no claims have been cancelled
  • A final written decision is expected within approximately one year

Financial Impact

Not stated in the decision; the patent's revenue contribution is not quantified

Risk Factors

  • Institution granted means the patent faces a substantive challenge; a final written decision could cancel some or all claims
  • The patent's revenue contribution to Novartis is not disclosed in the decision, making materiality uncertain
  • Appeal to the Federal Circuit is possible after a final written decision

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
44% bullish (34 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 PTAB decision.

DocumentAccession Number
PTAB-TRIAL Data (Synthetic)ptab-IPR2026-00260-ins-NVS

Track record

16 reports on NVS

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +6.86% at T+60 after the Jul 1, 2026 report. 5 of 6 went positive at some point.

Filters
  1. Nov 12, 20264d ago 6-K Neutral 3/10 Entry $160.50 to $160.20 Now $160.20 −0.19% ▼ −0.19% +1.72% vs SPY
  2. Nov 10, 20267d ago PTAB Trial Neutral 3/10 Viewing Entry $163.26 to $160.32 Now $160.20 −1.87% ▼ −1.80% −3.12% vs SPY
  3. Oct 28, 202619d ago 144 Neutral 2/10 Entry $156.08 to $161.10 Now $160.20 +2.64% ▲ +3.22% +3.60% vs SPY
  4. Oct 27, 202620d ago 6-K Mixed 6/10 Entry $156.86 to $156.08 Now $160.20 +2.13% ▼ −0.50% −0.84% vs SPY
  5. Oct 15, 20264w ago Court Ruling Neutral 2/10 Entry $150.62 to $150.20 Now $160.20 +6.36% ▼ −0.28% −0.70% vs SPY
  6. Oct 13, 20265w ago Court Ruling Bearish 5/10 Entry $146.88 to $150.38 Now $160.20 −9.07% ▼ −2.38% −2.10% vs SPY
  7. Sep 22, 20267w ago Institutional Cluster Mixed 4/10 Entry $141.28 to $142.71 Now $160.20 +13.39% ▲ +1.01% +1.73% vs SPY
  8. Sep 4, 202610w ago 6-K Bearish 6/10 Entry $137.70 to $137.48 Now $160.20 −16.34% ▲ +0.16% −0.30% vs SPY
  9. Sep 1, 202610w ago 6-K Bullish 7/10 Entry $161.25 to $162.46 Now $160.20 −0.65% ▲ +0.75% +0.31% vs SPY
  10. Aug 4, 202615w ago Court Ruling Neutral 2/10 Entry $154.44 to $154.21 Now $160.20 +3.73% ▼ −0.15% +0.01% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 9h 13m

Subscribe to SecBot

Get Real-Time PTAB Decision Intelligence

Market-moving PTAB patent decisions analyzed within minutes. Trial institutions, denials, final written decisions, and more, parsed and scored by AI.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
⚖ PTAB Decision · ptacts.uspto.gov Report published Nov 10, 2026